瑞舒伐他汀降低卵巢癌术后循环组织因子细胞外囊泡的疗效。

IF 7.1 1区医学 Q1 HEMATOLOGY

Blood advances Pub Date : 2025-09-09 DOI:10.1182/bloodadvances.2025016107

Soravis Osataphan, Rushad Patell, Mrigya Babuta, Rachel P Rosovsky, Yohei Hisada, Charly Edmiston, Pavania Elavalakanar, Michael A Pfeffer, Amy Bregar, Amanda Ramos, Leslie Garrett, Siyang Ren, Donna Neuberg, Gyongyi Szabo, Robert Flaumenhaft, Nigel Mackman, Meghan Shea, Jeffrey I Zwicker

引用次数: 0

摘要

静脉血栓栓塞在卵巢癌中很常见，尤其是手术后。携带组织因子的细胞外囊泡（TF+EV）的细化与癌症血栓形成和手术高凝性有关。瑞舒伐他汀可以减少非癌症人群中eve的产生并降低VTE的风险。卵巢癌手术后使用瑞舒伐他汀通过降低TF+EV来减轻术后血栓形成尚未研究。在一项针对卵巢癌患者的2期试验中，女性随机接受依诺肝素40 mg /天，连续30天，同时或不同时服用瑞舒伐他汀40 mg /天（从第15- 60天开始给药）。选择放弃随机分组的妇女每天接受依诺肝素40毫克，连续30天。在基线、第30天和第60天评估总EV和TF+EV。第30、60天行双侧下肢超声检查。共有24名妇女参加了这项试验，15名妇女接受了随机分组，7名妇女随机分配到依诺肝素联合瑞舒伐他汀组（17名妇女单独接受依诺肝素组）。在第30天或第60天，瑞舒伐他汀加依诺肝素组循环TF+EV无统计学差异。同样，c -反应蛋白和d -二聚体在两组之间也没有差异。超声筛查未发现下肢深静脉血栓形成，仅依诺肝素组诊断出门静脉血栓形成。未见大出血。卵巢癌手术后依诺肝素加瑞舒伐他汀似乎不会影响循环TF+EV的数量，也不会改变血栓炎症标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

The efficacy of rosuvastatin to reduce circulating tissue factor extracellular vesicles after ovarian cancer surgery.

查看原文本刊更多论文

The efficacy of rosuvastatin to reduce circulating tissue factor extracellular vesicles after ovarian cancer surgery.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Blood advances Medicine-Hematology

CiteScore

12.70

自引率

2.70%

发文量

840

期刊介绍： Blood Advances, a semimonthly medical journal published by the American Society of Hematology, marks the first addition to the Blood family in 70 years. This peer-reviewed, online-only, open-access journal was launched under the leadership of founding editor-in-chief Robert Negrin, MD, from Stanford University Medical Center in Stanford, CA, with its inaugural issue released on November 29, 2016. Blood Advances serves as an international platform for original articles detailing basic laboratory, translational, and clinical investigations in hematology. The journal comprehensively covers all aspects of hematology, including disorders of leukocytes (both benign and malignant), erythrocytes, platelets, hemostatic mechanisms, vascular biology, immunology, and hematologic oncology. Each article undergoes a rigorous peer-review process, with selection based on the originality of the findings, the high quality of the work presented, and the clarity of the presentation.